In a filing, Verona Pharma Plc ADR revealed its General Counsel Fisher Andrew unloaded Company’s shares for reported $0.69 million on May 15 ’25. In the deal valued at $8.57 per share,80,000 shares were sold. As a result of this transaction, Fisher Andrew now holds 359,999 shares worth roughly $26.13 million.
Then, ACKERMANN CHRISTINA sold 40,000 shares, generating $337,600 in total proceeds. Upon selling the shares at $8.44, the Director now owns 41,880 shares.
Before that, ANDREW FISHER bought 30,000 shares. Verona Pharma Plc ADR shares valued at $2,017,200 were divested by the Officer at a price of $67.24 per share.
TD Cowen initiated its Verona Pharma Plc ADR [VRNA] rating to a Buy in a research note published on April 28, 2025; the price target was $100. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. ROTH MKM began covering VRNA with “Buy” recommendation on January 10, 2025. Wells Fargo started covering the stock on October 03, 2024. It rated VRNA as “an Overweight”.
Price Performance Review of VRNA
On Monday, Verona Pharma Plc ADR [NASDAQ:VRNA] saw its stock jump 1.78% to $72.58. Over the last five days, the stock has gained 7.48%. Verona Pharma Plc ADR shares have risen nearly 56.29% since the year began. Nevertheless, the stocks have risen 420.29% over the past one year.
How much short interest is there in Verona Pharma Plc ADR?
A steep rise in short interest was recorded in Verona Pharma Plc ADR stocks on 2025-04-30, dropping by -1.12 million shares to a total of 8.0 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 9.13 million shares. There was a decline of -14.05%, which implies that there is a negative sentiment for the stock.
